Source: Pi-Sunyer X et al. N Engl J Med. 2015;373:11-22 (SCALE). Marso SP et al. N Engl J Med. 2016;375:311-322 (LEADER). Results with diet + exercise. Individual results vary.
FDA-Approved
Once Daily · GLP-1
Licensed US · Canada · UK pharmacies
Saxenda at a glance
FDA-approved for chronic weight management in adults with obesity or overweight + ≥1 condition.
Active ingredient: liraglutide 3mg — the same GLP-1 hormone naturally released after eating.
Avg 8.0% body weight lost at 56 weeks (SCALE trial, with diet + exercise).
63% of patients achieved ≥5% weight loss; 33% achieved ≥10%.
80% of prediabetes patients reverted to normal blood sugar (SCALE Prediabetes).
Once-daily injection — fine-tuned daily dosing control preferred by some patients.
Avg 8% body weight lost — SCALE trial, 56 weeks with diet + exercise
Saxenda® (liraglutide 3mg) is an FDA-approved, once-daily GLP-1 receptor agonist for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition, used with a reduced-calorie diet and increased physical activity. At Vitercure, eligible adults can complete
a brief online intake, consult with a licensed clinician via HIPAA-secure telehealth, and receive
a Saxenda prescription dispensed from licensed US, Canadian, or UK partner pharmacies with
temperature-controlled shipping — no lengthy in-person visit required.
Individual results vary. Always speak with your clinician about realistic personal expectations.
NV
"Lost 24 lbs over 5 months on Saxenda. I tried other approaches for years. The daily injection was manageable — you get into a routine and it becomes easy."
24 lbs · 5 months · 3mg
JW
"My A1C was in prediabetes range. After 6 months on Saxenda my blood sugar is normal again. I also lost 19 lbs as a bonus. My doctor was thrilled."
19 lbs · Prediabetes reversed · 3mg
CL
"I switched to Saxenda from a weekly GLP-1 because I wanted more control over my dosing. The daily schedule helped me adjust side effects much more easily."
Daily control · GLP-1 transition
What is Saxenda® (Liraglutide)?
Saxenda (liraglutide 3mg) is an FDA-approved, once-daily GLP-1 receptor agonist for chronic weight
management developed by Novo Nordisk. It is a synthetic analogue of GLP-1 — a naturally occurring
hormone released after eating that signals fullness to the brain and slows digestion. At the 3mg dose,
Saxenda is specifically indicated for weight management, distinguishing it from Victoza (liraglutide
1.2–1.8mg), which is used for type 2 diabetes.
How Saxenda works — dual appetite and metabolic action
Appetite regulation in the brain
Saxenda binds to GLP-1 receptors in the hypothalamus — the brain region controlling hunger. It reduces appetite signals, decreases food cravings, and promotes a sense of satiety independent of what you eat.
Slower gastric emptying
By slowing how quickly food leaves the stomach, Saxenda prolongs the feeling of fullness after meals — naturally reducing portion sizes and snacking without extreme restriction.
Who qualifies for Saxenda?
Saxenda is indicated for adults with a BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one
weight-related condition — such as high blood pressure, type 2 diabetes, high cholesterol, obstructive
sleep apnea, or cardiovascular disease. It is also approved for adolescents aged 12+ with obesity.
A Vitercure clinician will review your full health profile before any prescription is issued.
Why some patients prefer Saxenda over weekly GLP-1s
The once-daily dosing schedule gives clinicians and patients more flexibility to titrate and manage
side effects gradually. For patients who are particularly sensitive to GI side effects — nausea, stomach
discomfort — the ability to adjust the daily dose in smaller steps can improve tolerability compared to
the larger weekly jumps in medications like Wegovy or Ozempic. Some patients also find that daily
injections feel like a stronger behavioral anchor to their routine.
Saxenda for prediabetes and blood sugar
The SCALE Prediabetes trial demonstrated that 80% of patients on liraglutide 3mg reverted to
normoglycemia at 56 weeks — compared to 45.5% on placebo. Saxenda also reduced progression to
type 2 diabetes by 80% over 3 years in this population. For patients with prediabetes and elevated
body weight, Saxenda represents one of the most evidence-supported pharmacological interventions.
Saxenda Weight Loss Results — SCALE Trial Data
The SCALE (Satiety and Clinical Adiposity — Liraglutide Evidence in Individuals with and without Diabetes)
program is the pivotal trial series establishing Saxenda's effectiveness, enrolling over 5,000 patients
across multiple sub-studies.
SCALE Obesity & Prediabetes — Primary Trial
N=3,731 adults with obesity (BMI ≥30) or overweight (BMI ≥27) + ≥1 condition. 56 weeks on
once-daily liraglutide 3mg + diet + exercise vs placebo.
8.0%
Avg body weight lost (vs 2.6% placebo)
63%
Achieved ≥5% weight loss
33%
Achieved ≥10% weight loss
14%
Achieved ≥15% weight loss
Source: Pi-Sunyer X et al. N Engl J Med. 2015;373:11-22.
SCALE trial outcomes across populations
Saxenda SCALE trial weight loss outcomes by population
Trial
Population
Avg weight loss (liraglutide)
Key finding
SCALE Obesity & Prediabetes
N=3,731 · Obesity/overweight
8.0% body weight
63% lost ≥5%; 33% lost ≥10%
SCALE Prediabetes
N=2,254 · Prediabetes
6.1% body weight
80% reverted to normoglycemia; 80% T2D risk reduction at 3 yrs
SCALE Diabetes
N=846 · Type 2 diabetes
6.0% body weight
0.9% A1C reduction vs 0.4% placebo
SCALE Maintenance
N=422 · After diet-induced loss
+6.2% maintained
Saxenda patients maintained 6.2% more weight lost than placebo
All outcomes at 56 weeks with diet + exercise unless noted. Sources: SCALE trial program, N Engl J Med. 2015–2016.
Saxenda weight loss timeline — what to expect month by month
Timeframe
Typical dose
What to expect
Week 1
0.6mg/day
Adjustment phase. GI side effects most common. Modest appetite changes begin.
Weeks 2–4
1.2–1.8mg/day
Appetite reduction more noticeable. First 2–5 lbs loss typical.
Month 2
2.4–3.0mg/day
Full therapeutic dose. Weight loss accelerates. Most patients on 3mg by month 2.
Months 3–6+
3.0mg/day
SCALE trial: avg 8% total body weight at 56 weeks. Most loss in months 3–6. Plateau common in month 5–6.
In 9,340 adults with type 2 diabetes and high cardiovascular risk, liraglutide reduced the composite
of CV death, non-fatal myocardial infarction, and non-fatal stroke by 13% versus placebo (LEADER trial).
While this data is in a T2D population, it reinforces liraglutide's cardiometabolic profile at
therapeutic doses relevant to Saxenda patients.
Source: Marso SP et al. N Engl J Med. 2016;375:311-322.
How Saxenda® Works & Dosing Guide
Administration basics
Form: Pre-filled multi-dose pen for once-daily subcutaneous injection.
Route: Subcutaneous (under the skin) — abdomen, thigh, or upper arm.
Frequency: Once daily, at the same time each day.
Timing: Any time of day, with or without food.
Storage: Refrigerate unused pens (36–46°F). In-use pens may be stored at room temperature for up to 30 days.
Site rotation: Rotate injection sites to prevent skin reactions.
Standard dose escalation schedule
Week
Daily dose
Purpose
Week 1
0.6mg
Starter — assesses tolerability. GI effects most common here.
Week 2
1.2mg
First step-up if 0.6mg tolerated.
Week 3
1.8mg
Appetite changes more noticeable.
Week 4
2.4mg
Near-therapeutic. Weight loss typically accelerates.
Week 5+
3.0mg
Full therapeutic maintenance dose. SCALE trial data at this dose.
This schedule is a general reference. Your clinician determines your personal dose. Never adjust or stop without consulting your prescriber.
Why daily dosing has advantages: The once-daily format allows for smaller, more controlled dose increments than weekly GLP-1s. If you are experiencing GI side effects, your prescriber can hold you at a lower daily dose longer — an option not available with weekly injections.
Saxenda® vs Wegovy, Ozempic, Zepbound & Mounjaro
The most common comparison queries for Saxenda center on how it compares to weekly GLP-1 medications —
Wegovy, Ozempic — and the dual-agonist options Zepbound and Mounjaro. Here is a direct clinical comparison.
Comparison of Saxenda vs Wegovy vs Ozempic vs Zepbound vs Mounjaro
Feature
Saxenda®
Wegovy®
Ozempic®
Zepbound®
Active ingredient
Liraglutide 3mg
Semaglutide 2.4mg
Semaglutide 2mg
Tirzepatide 15mg
Mechanism
GLP-1 only
GLP-1 only
GLP-1 only
Dual GIP + GLP-1
Weight loss FDA approval
Yes — Saxenda
Yes — Wegovy
No (off-label)
Yes — Zepbound
Avg weight loss (trial)
8.0% (SCALE, 56 wks)
15.3% (STEP-1)
~6–9% (SUSTAIN-1)
22.5% (SURMOUNT-1)
Dosing frequency
Once daily
Once weekly
Once weekly
Once weekly
Dose titration steps
5 weekly steps (more control)
5 monthly steps
4 monthly steps
6 monthly steps
GI side effect control
High — daily micro-titration
Moderate
Moderate
Moderate
CV outcomes trial
LEADER (13% reduction)
SELECT (20% reduction)
SUSTAIN-6 (26% reduction)
SURMOUNT-MMO (ongoing)
Clinical comparisons are for educational purposes only. A licensed clinician determines the most appropriate treatment for you. Weight loss averages include diet + exercise in all trials.
When Saxenda may be preferred
Patients who want maximum flexibility to adjust dose for GI tolerance.
Those for whom weekly GLP-1s caused intolerable side effects.
Patients with prediabetes seeking both weight loss and glycemic reversal.
Daily routine anchor preferred over weekly injection schedule.
When your clinician may suggest an alternative
Primary goal is maximum weight loss (Zepbound 22.5% or Wegovy 15.3% may be considered).
Type 2 diabetes requiring simultaneous glycemic and weight management.
Saxenda® Cost & Access — Vitercure
Saxenda pricing varies by source country, number of pens, and whether you are purchasing starter or
maintenance packs. Vitercure offers transparent one-time pack pricing from US, Canadian, and UK
partner pharmacies with no automatic subscriptions.
What your cost may include
Telehealth intake + clinician evaluation
Saxenda prescription if clinically appropriate
Dispensed by licensed US/Canada/UK partner pharmacies
Temperature-controlled shipping
Vitercure weight-loss education library access
Saxenda cost without insurance
Novo Nordisk's US list price for Saxenda is approximately $1,450/month through retail pharmacies. Vitercure's pricing through international partner pharmacies is displayed in the pack selectors above, with starter options from $234.99.
Novo Nordisk savings programs: Eligible commercially insured patients may qualify for Novo Nordisk's savings card program. Ask your clinician or visit novonordisk-us.com for current program details.
Insurance coverage for GLP-1 weight-loss medications varies widely. Vitercure primarily operates as a cash-pay service. HSA/FSA funds may be applicable — confirm with your benefits provider.
Important Safety Information — Saxenda®
This is not a complete list of all warnings or side effects. Always review the full Prescribing Information and Medication Guide, and speak with a licensed clinician.
Boxed warning: thyroid C-cell tumors
Saxenda carries a boxed warning for possible thyroid C-cell tumor risk. Do not use if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your clinician about any neck lump, trouble swallowing, hoarseness, or shortness of breath.
Other serious risks
Serious side effects can include pancreatitis, gallbladder problems, kidney injury, serious allergic reactions, depression or suicidal thoughts, and low blood sugar (especially when combined with diabetes medications). Seek urgent care for severe abdominal pain, signs of allergic reaction, or sudden changes in mood or behavior.
Common side effects
The most frequently reported side effects include nausea, vomiting, diarrhea, constipation, decreased appetite, headache, dizziness, fatigue, and injection site reactions. GI effects are most pronounced during dose escalation and typically lessen as the body adjusts. Saxenda's daily titration allows for slower dose increases than weekly GLP-1s, which can help manage tolerability.
Saxenda and mental health
Unlike weekly GLP-1 medications, Saxenda's FDA label includes a warning for depression and suicidal thoughts — a distinction worth discussing with your clinician if you have a history of mood disorders. Report any mood changes, feelings of depression, or unusual thoughts to your prescriber immediately.
Saxenda® FAQ
In the SCALE Obesity & Prediabetes phase 3 trial (N=3,731, 56 weeks), adults on liraglutide 3mg plus diet and exercise lost an average of 8.0% of body weight — compared to 2.6% on placebo. 63% achieved ≥5% weight loss, 33% achieved ≥10%, and 14% achieved ≥15%. Individual results vary based on adherence, diet, activity, and starting weight.
Wegovy (semaglutide 2.4mg) produced average weight loss of 15.3% in STEP-1, and Zepbound (tirzepatide 15mg) produced 22.5% in SURMOUNT-1 — both higher than Saxenda's 8%. However, Saxenda's once-daily dosing allows for finer titration and better GI side effect management for sensitive patients. "Better" depends on your goals, tolerability, and medical history. Your Vitercure clinician will help you choose.
Saxenda is not FDA-approved specifically for PCOS, but liraglutide targets insulin resistance — a core mechanism in PCOS — and may improve menstrual regularity, reduce androgens, and support weight loss in women with PCOS. Growing clinical evidence supports its use in this population. Your Vitercure clinician will assess whether Saxenda is appropriate for your PCOS profile.
Yes — the SCALE Prediabetes trial showed that 80% of patients on liraglutide 3mg reverted to normoglycemia at 56 weeks, compared to 45.5% on placebo. Over 3 years, Saxenda reduced progression to type 2 diabetes by 80%. If prediabetes is a primary concern alongside weight, Saxenda is one of the most evidence-supported pharmacological options.
Saxenda (liraglutide) is a once-daily GLP-1 injection. Wegovy and Ozempic (semaglutide) are once-weekly GLP-1s — semaglutide is a structurally different molecule that stays active longer, allowing weekly dosing. Mounjaro and Zepbound (tirzepatide) are once-weekly dual GIP/GLP-1 agonists that typically produce greater weight loss than single GLP-1 options. Your clinician will weigh dosing preference, tolerability, and effectiveness when recommending the right medication.
Yes. Transitioning between GLP-1 medications is common — patients may switch for better weight loss, convenience, or tolerability. The transition requires careful planning by your prescriber to manage washout, dose equivalency, and timing. A Vitercure clinician can help plan a safe switch if you want to explore Wegovy, Zepbound, or Mounjaro.
Yes. Through Vitercure's HIPAA-secure telehealth platform, a licensed clinician can evaluate your health history remotely and, if appropriate, prescribe Saxenda without an in-person visit. Saxenda is prescription-only and cannot be legally dispensed without a valid prescription. A short online questionnaire begins the process.
The SCALE Maintenance trial showed that patients who discontinued liraglutide after an initial weight-loss period regained significant weight compared to those who continued treatment. Appetite typically returns, and weight regain begins within weeks to months. Never stop Saxenda without consulting your clinician, who can help you plan a safe transition or continuation strategy.
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach discomfort — most prominent during dose escalation and often improving with time. Saxenda's daily dosing allows slower titration, which some patients find helps manage GI effects better than weekly options. Saxenda also carries a mental health warning; contact your clinician if you experience mood changes or depression.
Saxenda vs Wegovy — Daily vs Weekly GLP-1 for Weight Loss
Both Saxenda (liraglutide 3mg) and Wegovy (semaglutide 2.4mg) are FDA-approved GLP-1 receptor agonists
for chronic weight management — but they differ in active ingredient, dosing frequency, and clinical
outcomes. Wegovy produced average weight loss of 15.3% of body weight in the STEP-1 trial, versus
Saxenda's 8.0% in SCALE. For many patients seeking maximum weight reduction, Wegovy is a stronger
pharmacological option. However, Saxenda's once-daily format provides one key practical advantage:
finer dose titration control.
Because Saxenda is injected daily, clinicians can increase the dose in 0.6mg weekly steps over five
weeks before reaching the 3mg therapeutic dose. This slower escalation gives the body more time to
adapt, and allows prescribers to hold the dose at a lower level if GI side effects are a concern.
Wegovy's monthly dose increases — while convenient — offer less flexibility when managing nausea
in sensitive patients. For patients who have struggled with GI intolerance on weekly GLP-1s, a
trial of Saxenda's daily format may be a clinically sound bridge or alternative.
Does Saxenda Work? What the SCALE Trials Actually Show
"Does Saxenda work?" is one of the most searched questions about this medication — and the SCALE
trial program provides a clear, evidence-based answer. In the primary SCALE Obesity and Prediabetes
trial (N=3,731, 56 weeks), adults on liraglutide 3mg with diet and exercise lost an average of
8.0% of their starting body weight. 63% achieved the clinically meaningful threshold of ≥5% weight
loss — the level associated with measurable improvements in blood pressure, cholesterol, and blood sugar.
Perhaps most impressively, SCALE Maintenance showed that patients who had already lost weight through
diet alone and then started Saxenda maintained 6.2% more weight loss than those given placebo — directly
demonstrating that Saxenda adds benefit beyond lifestyle change alone. The SCALE Prediabetes sub-study
showed 80% of patients reverting to normal blood sugar — a result that makes Saxenda one of the most
powerful evidence-based tools for preventing type 2 diabetes in high-risk patients.
Saxenda for PCOS — Insulin Resistance, Weight, and Hormonal Balance
PCOS affects up to 10% of women of reproductive age, and insulin resistance is central to its
pathophysiology. Elevated insulin drives increased androgen production in the ovaries — causing
irregular cycles, hirsutism, and difficulty losing weight. By improving insulin sensitivity through
GLP-1 receptor activation, liraglutide can interrupt this cycle: lower insulin leads to lower androgens,
which in turn may improve ovulation, reduce symptoms, and support metabolic health.
While Saxenda is not specifically FDA-approved for PCOS, multiple clinical trials have evaluated
liraglutide in PCOS populations, consistently showing improvements in menstrual regularity, androgen
levels, and weight. The combination of meaningful weight loss (8% SCALE trial average) and insulin-sensitizing
effects makes Saxenda a compelling option for women with PCOS who are struggling with weight-related
hormonal disruption. Your Vitercure clinician will determine whether Saxenda, metformin, or a combination
is most appropriate for your individual profile.
“
Clinician perspective on Saxenda
I reach for Saxenda in two specific situations. First, patients who have tried weekly GLP-1s
and found the GI side effects unmanageable — the daily titration gives us much more room to
find a comfortable dose. Second, patients with prediabetes who want to reverse their trajectory
toward type 2 diabetes: the SCALE Prediabetes data is remarkable, with 80% achieving
normoglycemia. For maximum weight loss, newer options generally outperform Saxenda — but for
tolerability and prediabetes, it remains a genuinely useful tool.
General perspective only. A Vitercure clinician will review your full health profile before any treatment recommendation.
Medically Reviewed
Dr. Jane Rote, MD
Board-Certified in Endocrinology & Metabolism
Last medical review: November 2025
Content reviewed for clinical accuracy
Start your Saxenda® journey with Vitercure
Answer a brief questionnaire. A licensed clinician reviews your history and may prescribe Saxenda
from licensed US, Canadian, or UK pharmacies — with temperature-controlled shipping. No lengthy
in-person visit required.
